Korro Bio, Inc. Restricted Cash and Cash Equivalents
Korro Bio, Inc. (KRRO) had Restricted Cash and Cash Equivalents of $27.31 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-08-06
- 2026-06-30: Restricted Cash and Cash Equivalents $27.31M.
- 2026-03-31: Restricted Cash and Cash Equivalents $65.10M.
- 2025-12-31: Restricted Cash and Cash Equivalents $25.23M.
- 2025-09-30: Restricted Cash and Cash Equivalents $27.56M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $27.31M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $65.10M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $25.23M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $27.56M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $37.02M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $67.55M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $59.05M 10-K · filed 2026-03-12 |
| 2024-09-30 | $68.38M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $96.33M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $145.76M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $173.12M 10-K · filed 2025-03-18 |
| 2022-12-31 | $41.48M 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |